Back grey_arrow_rt.gif
 
 
Fuzeon Drug Sales Fall in 4Q
Fuzeon HIV Drug Sales Fall During the 4th-Quarter on Lagging U.S., Canadian Markets
 
 
  January 29, 2008: 05:43 PM EST
 
NEW YORK (Associated Press) - Biotechnology company Trimeris Inc. said Tuesday that worldwide sales of its HIV treatment Fuzeon fell 9 percent during the fourth quarter, weighed down by lagging U.S. and Canadian sales.
 
The company said worldwide sales fell 9 percent to $66.5 million from $73.3 million. In the U.S. and Canada, sales fell 25 percent to $31.5 million from $42.2 million. Outside of the U.S. and Canada, sales rose 13 percent to $35 million from $31.1 million.
 
For the full year, sales rose 7 percent worldwide to $266.8 million from $249 million, buoyed by international sales. Canadian and U.S. sales fell 7 percent to $124.3 million, but international sales rose 24 percent to $142.5 million.
 
Trimeris said it will release full financial results for 2007 in early March.
 
Shares of Trimeris rose 2 cents to $6.57 in after-hours trading after falling 24 cents, or 3.5 percent, to close at $6.55 during regular trading
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org